EUVIMEDEUVIMED entdecken
Kohortenstudie

Endometrial cancer risk with menopausal hormone therapy: Health Insurance Database in South Korea‐based cohort study

Jin-Sung Yuk iD

International Journal of Gynecology & Obstetrics · 2023

DOI: 10.1002/ijgo.14753 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift International Journal of Gynecology & Obstetrics, 2023. Verfasst von Jin-Sung Yuk. Beteiligte Einrichtung: Department of Obstetrics and Gynecology, Sanggye Paik Hospital, School of Medicine, Inje University, Seoul, Republic of Korea. Hauptthemen laut MEDLINE: Progestins, Endometrial Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 38 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

To determine the risk of endometrial cancer according to the types of menopausal hormones used.

Methods

This retrospective cohort study recruited postmenopausal women older than 40 years from 2003 to 2011, utilizing data from the Korean national health insurance system from 2002 to 2019. The menopausal hormone therapy (MHT) group consisted of women who had been prescribed MHT for greater than 6 months between 2003 and 2011. The non‐MHT group consisted of women who had never used menopausal hormones between 2003 and 2011.

Results

A non‐MHT group of 1 000 550 women and a MHT group of 353 025 women were chosen. In comparison to never‐users, the risk of endometrial cancer was not higher in women who reported last using tibolone (adjusted hazard ratio [aHR] 1.08, 95% confidence interval [CI] 0.96–1.2), combined estrogen plus progestin by the manufacturer (aHR 0.83, 0.72–0.96), combined estrogen plus progestin by the physician (aHR 0.88, 0.7–1.12), and transdermal estrogen (aHR 1.13, 0.36–3.52).

Conclusions

Tibolone, combined estrogen plus progestin by the physician, and transdermal estrogen do not affect the risk of endometrial cancer. The combination of estrogen plus progestin by the manufacturer decreases the risk of endometrial cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ProgestinsEndometrial NeoplasmsFemaleHumansCohort StudiesRetrospective StudiesPostmenopauseEstrogensEstradiolMenopauseInsurance, HealthEstrogen Replacement Therapy

Stichwörter der Autor:innen

endometrial cancermenopausal hormone therapytibolone

Substanzen

ProgestinsEstrogensEstradiol

Autor:innen und Institutionen

  • Department of Obstetrics and Gynecology, Sanggye Paik Hospital, School of Medicine, Inje University, Seoul, Republic of Korea.

ORCID-Profile: Jin-Sung Yuk

Zitieren

APA

Yuk, J. S. (2023). Endometrial cancer risk with menopausal hormone therapy: Health Insurance Database in South Korea‐based cohort study. International Journal of Gynecology & Obstetrics. https://doi.org/10.1002/ijgo.14753

Vancouver

Yuk JS. Endometrial cancer risk with menopausal hormone therapy: Health Insurance Database in South Korea‐based cohort study. International Journal of Gynecology & Obstetrics. 2023. doi:10.1002/ijgo.14753

BibTeX
@article{Yuk2023,
  author = {Yuk, Jin-Sung},
  title = {Endometrial cancer risk with menopausal hormone therapy: Health Insurance Database in South Korea‐based cohort study},
  journal = {International Journal of Gynecology & Obstetrics},
  year = {2023},
  doi = {10.1002/ijgo.14753}
}
Kostenlos starten →